Loading...
Market
How many new GLP-1 drugs will be approved for diabetes treatment by July 31, 2025?
2
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
FDA approvals and announcements
Story
Study Finds Ozempic, Wegovy Lower Cancer Risk in Type 2 Diabetes Patients by 10 out of 13
Jul 5, 2024, 05:09 PM
A new study has found that GLP-1 drugs, including Ozempic and Wegovy, significantly reduce the risk of cancer in patients with type 2 diabetes. The retrospective cohort study, which analyzed electronic health records of approximately 1.65 million people over 15 years, revealed that patients on GLP-1 medications had a lower risk for 10 out of 13 obesity-related cancers compared to those on insulin therapy. The findings, published Friday in JAMA Network Open, were based on data from 113 million US patients and suggest a promising alternative for reducing cancer risk in diabetic patients.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
None • 25%
1 company • 25%
2 companies • 25%
3 or more companies • 25%
Zepbound • 25%
Wegovy • 25%
Ozempic • 25%
Other • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%